The CCHI IOFM Core funded six applications submitted in response to our RFA released August 31, 2020. The CCHI Steering Committee sought applications from CCHI centers to capitalize on emerging opportunities and encourage multi-center, multi-disciplinary collaborations. The immediate objective of the CCHI is to support mechanistic and hypothesis-testing studies to understand human immunity applicable to the biodefense effort (i.e. innate, adaptive and mucosal immune responses to infection, vaccination and adjuvants). Studies on immune-mediated diseases (e.g. airway allergy, food allergy, autoimmunity, organ transplant rejection) are also of interest, as these data will provide a more comprehensive understanding of the human immune system.
Sean Brady, PhD from Rockefeller University applied from the Rockefeller University CCHI U19 Center (Ravetch, PD/PI). Project is entitled “Human-microbial-lectins regulate the mucosal immune system”
Junyue Cao, PhD from Rockefeller University applied from the Rockefeller University CCHI U19 Center (Ravetch, PD/PI). Project is entitled “Investigation of the pathogenesis of Psoriasis through a novel single-cell genomic technique”
Shirit Einav, MD from Stanford University applied from the Stanford University CCHI U19 Center (Davis, PD/PI). Project is entitled “Unique human lung organoids to study COVID-19 pathogenesis and therapy response”
Marc K. Hellerstein, MD, PhD from the University of California, Berkeley applied from the Emory University CCHI U19 Center (Ahmed, PD/PI). The project is entitled “Lifespan of SARS-CoV-2 reactive T-cells in COVID-19: Rationale for T-cell based vaccines”
William Hildebrand, PhD, MA from the University of Oklahoma Health Sciences Center applied from the Oklahoma Medical Research Foundation CCHI U19 Center (Coggeshall, PD/PI). The Core is entitled “HLA Typing Core”
Troy Randall, PhD from the University of Alabama at Birmingham applied from the UAB CCHI U19Center (Lund, PD/PI). Project is entitled “Lung-resident memory B and T cells from COVID-19 convalescent patients”
